At the Ophthalmology Futures Forum Europe 2014 today, initial results were previewed from a Salutaris Medical Devices, Ltd. (SalutarisMD®) sponsored observational study conducted at Moorfields Eye Hospital NHS Foundation Trust. This study is a forerunner to upcoming multi-center interventional studies to be led by Moorfields.

PRLog – Sep.11, 2014 – LONDON, UK — In 2013, Moorfields and SalutarisMD announced their collaboration to advance the research and development of a novel medical device for use in the treatment of wet age-related macular degeneration (AMD), the leading cause of vision loss and blindness.

The purpose of this study was to accurately measure the scleral and choroid thickness at the fovea and at the choroidal neovascular lesion.  This observational study (“A Prospective Study to Determine Choroidal and Scleral Depth in Subjects with Neovascular Age-related Macular Degeneration Receiving Anti-VEGF Therapy”) used three imaging modalities to determine the depth from the retrobulbar episcleral surface to the vitreous side of the sclera, choroid, and retina at the centre of the fovea and choroidal neovascularisation (CNV).

The SalutarisMD device employs a minimally invasive retrobulbar episcleral brachytherapy application to the neovascular membranes.  The differentiation and measurement of the retina, choroid and sclera layers is of particular importance in determining the depth from the outer surface of the eye, through the choroid, to the apex of the CNV. Distance from the episcleral surface to the choroidal lesion is the key to delivering the appropriate prescribed radiation dose and the results of this study will ensure accurate dosimetry.

Enrollment of study subjects has been completed. “We were very excited to conclude this study with our research collaborators at Moorfields Eye Hospital,” said Dr. Laurence Marsteller, Managing Director of SalutarisMD, Ltd.  “The resultant data will bring us closer to offering this new therapy to patients suffering from wet AMD.”

Wet AMD has a profoundly negative impact on quality of life and imposes a considerable financial burden on healthcare systems. An estimated 70 percent of patients with wet AMD will experience severe vision loss within two years of receiving the diagnosis. There is an urgent and compelling need for new therapies that improve visual outcomes and lower the burden of care. The SalutarisMD device has the potential to accomplish these aims by reducing the need for repeated monthly injections and eliminating or extending the period between treatments.

Note to Editors

Salutaris Medical Devices, Ltd. (SalutarisMD®) is a clinical-stage medical device company dedicated to developing minimally invasive, patient-centric treatments for vision loss. For more information about SalutarisMD visit

Salutaris Medical Devices, Ltd. 

Level 1, Bessemer Building, Imperial College, London SW72AZ, +44 (0) 203 282 7166,

Salutaris Medical Devices, Inc.

 4330 N. Campbell Ave.,Tucson, AZ 85718, +1 520-638-7518,

Salutaris Medical Devices media contact details:
UK Communications Director, Ms. Amanda Thomas,
US Communications Director, Ms. Joanne Vitali,,  +001 610-518-5405

Moorfields Eye Hospital NHS Foundation Trust is one of the world’s leading eye hospitals, providing expertise in clinical care, research and education.  Moorfields has provided excellence in eye care for more than 200 years and continues to be at the forefront of new breakthroughs and developments.   Moorfields is an integral part of one of the UK’s first academic health science centres, UCL Partners, and were one of the first organisations to become an NHS foundation trust in 2004.  For further information, please visit

Moorfields Eye Hospital NHS FT press office contact details:
Telephone 020 7566 2628 or email

Caution: Investigational Device. Limited by Federal Law to Investigational Use in the United States.